New Work With Volition
We’ve been helping our clients, Volition, quoted on the New York Stock Exchange, with a flurry of interviews and announcements surrounding their activities on their own website and also on social media outlets.
We crafted a special video invitation in our own Green Screen studio to their event which ties in with the 9th Annual Biotech Showcase Conference being held from January 9-11, 2017 in San Francisco, CA. At the Biotech Showcase, Cameron Reynolds, Chief Executive Officer of Volition, will provide an update on Volition’s business, clinical, regulatory and operational milestones, 
as well as the Company’s recently announced product launch of its Nu.QTM Colorectal Cancer Screening Triage Test.
We also interviewed Cameron Reynolds about the company’s latest set of results. Click here to see the latest videos.
Volition is a multi-national company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.
Volition has also entered into a Memorandum of Understanding (“MOU”) with the National Taiwan University (“NTU”) to conduct two large colorectal cancer (CRC) research studies across the Asia Pacific Region, totaling approximately 7,000 patient samples. Subject to agreement on the terms and conditions, the Parties intend to sign a binding CRC Study Agreement in the first quarter of 2018.
“The signing of this MOU is a good start for Volition in the Asia Pacific Region” commented Dr. Jasmine Kway, Volition’s Vice President of Asia. “We are fortunate and delighted to be working with a renowned institution and Professor Han-Mo Chiu, a prominent thought leader. This large-scale study will be low cost in line with Volition’s other great value studies such as the 13,500-subject study in the U.S. and the ongoing 30,000-subject prospective study in Europe and demonstrates our commitment to conducting large trials worldwide to drive the acceptance of our products.”
